

Docket No. 259880US0X PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Romain VIVES, et al.

SERIAL NO: 10/509,686

GAU:

FILED: October 12, 2004

EXAMINER:

FOR: ANTI-HIV COMPOSITION, METHOD OF PRODUCTION AND MEDICINAL PRODUCT

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).


## CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>259880US0X PCT</b>		SERIAL NO. <b>10/509,686</b>	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT <b>Romain VIVES, et al.</b>			
				FILING DATE <b>October 12, 2004</b>		GROUP	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES                      NO		
	AD	92 04909	04/02/92	WO		NO	
	AE	0 332 952	09/20/89	EP		NO	
	AF	0 249 390	12/16/87	EP		NO	
	AG	02 059146	08/01/02	WO (with English abstract)		NO	
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AH	WITVROUW, M. et al. "Sulfated Polysaccharides Extracted from Sea Algae as Potential Antiviral Drugs", Gen. Pharmac., vol. 29, no. 4, pages 497-511, XP002056013 1997					
	AI	MOULARD, Maxime et al. "Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120", Journal of Virology, vol. 74, no. 4, pages 1948-1960, XP002226781 2000					
	AJ	SULLIVAN, Nancy et al. "Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies", Journal of Virology, vol. 72, no. 8, pages 6332-6338, XP002226782 1998					
	AK	HARROP, Hilary A. et al. "Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding", AIDS, vol. 8, no. 2, pages 183-192, XP002226783 1994					
	AL	CHAN, David C. et al. "HIV Entry and Its Inhibition", Cell, vol. 93, pages 681-684 1998					
	AM	CLAPHAM, Paul R. "HIV and chemokines: ligands sharing cell-surface receptors", Trends in Cell Biology, vol. 7, pages 264-268 1997					
	AN	MICHAEL, Nelson L. et al. "HIV-1 entry inhibitors: Evading the Issue", Nature Medicine, vol. 5, no. 7, pages 740-742 1999					
	AO	CHAN, David C. et al. "Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target", Proc. Natl. Acad. Sci. vol. 95, pages 15613-15617 1998					
	AP	DOMS, Robert W. et al. "HIV-1 Membrane Fusion: Targets of Opportunity", The Journal of Cell Biology, vol. 151, no. 2, pages F9-F13 2000					
	AQ	SCHENTEN, Dominik et al. "Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells", Journal of Virology, vol. 73, no. 7, pages 5373-5380 1999					
	AR	CHEN, Ji-Dai et al. "Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy", Nature Medicine, vol. 3, no. 10, pages 1110-1116 1997					
	AS	OBERLIN, Estelle et al. "The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1", Nature, vol. 382, pages 833-835 1996					
	AT	PROUDFOOT, Amanda et al. "Chemokine Receptors-Future Therapeutic Targets for HIV?" Biochemical Pharmacology, vol. 57, pages 451-463 1999				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 259880US0X PCT		SERIAL NO. 10/509,686	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Romain VIVES, et al.			
				FILING DATE October 12, 2004		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AU	MURAKAMI, Tsutomu et al. "A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection", J. Exp. Med., vol. 186, no. 8, pages 1389-1393 1997					
	AV	MONDOR, Isabelle et al. "Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans", Journal of Virology, vol. 72, no. 5, pages 3623-3634 1998					
	AW	RODERIQUEZ, Gregory et al. "Mediation of Human Immunodeficiency Virus Type 1 Binding by Interaction of Cell Surface Heparan Sulfate Proteoglycans with the V3 Region of Envelope gp120-gp41", Journal of Virology, vol. 69, no.4, pages 2233-2239 1995					
	AX	ABRAMS, Donald I. et al. "Oral Dextran Sulfate (UA001) in the Treatment of the Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex", Annals of Internal Medicine, vol. 110, no. 3, pages 183-188 1989					
	AY	FLEXNER, Charles et al. "Pharmacokinetics, Toxicity, and Activity of Intravenous Dextran Sulfate in Human Immunodeficiency Virus Infection", Antimicrobial Agents and Chemotherapy, vol. 35, no. 12, pages 2544-2550 1991					
	AZ	CHERNYAK, Anatoly et al. "Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand", Carbohydrate Research, vol. 330, pages 479-486 2001					
	AAA	KUBERAN, B. et al. "Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes", Glycoconjugate Journal, vol. 16, pages 271-281 1999					
	AAB	NAJJAM, Saloua et al. "Characterization of Human Recombinant Interleukin 2 Binding to Heparin and Heparan Sulfate Using an Elisa Approach", Cytokine, vol. 9, no. 12, pages 1013-1022 1997					
	AAC	DREEF-TROMP, C.M. et al. "Biological Properties of Synthetic Glycoconjugate Mimics of Heparin Comprising Different Molecular Spacers", Bioorganic and Medicinal Chemistry Letters, vol. 8, pages 2081-2086 1998					
	AAD	GROOTENHUIS, P.D. et al. "Rational Design of Synthetic heparin analogues with tailor-made coagulation factor inhibitory activity", Nature Structural Biology, vol. 2, no. 9, pages 736-739 1995					
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PCT Application Serial No.: 10/509,686  
Docket No.: 259880US0X PCT

#### STATEMENT OF RELEVANCY

- 1) References AD-AK have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of these references is being submitted herewith.
- 3) References AL-AAD are discussed in the specification. A copy of these references is being submitted here with.
- 4) References \_\_\_\_\_ are additional prior art known to Applicant. A copy of these references is being submitted herewith.